montelukast sold brand name singulair among others medication used maintenance treatment generally less preferred use inhaled useful acute asthma uses include allergic rhinitis hives long allergic rhinitis secondline common side effects include abdominal pain cough severe side effects may include allergic reactions anaphylaxis use pregnancy appears montelukast leukotriene receptor antagonist family works blocking action leukotriene lungs resulting decreased inflammation relaxation smooth montelukast approved medical use united states available generic fourteenth commonly prescribed medication united states million montelukast used number conditions including asthma exercise induced bronchospasm allergic rhinitis mainly used complementary therapy adults addition inhaled corticosteroids inhaled steroids alone bring desired effect also used prevent allergic reactions asthma flareups administration intravenous immunoglobulin may also used adjunct therapy symptomatic treatment taken mouth tablet chewable tablet common side effects include diarrhea nausea vomiting mild rashes asymptomatic elevations liver enzymes fever uncommon side effects include fatigue malaise behavioral changes paresthesias seizures muscle cramps nose bleeds rare may affect people taking montelukast serious side effects include behavioral changes including suicidal thoughts angioedema erythema multiforme liver concerns neuropsychiatric reactions added label united kingdom united states frequently suspected nightmares depression insomnia may affect people taking montelukast aggression anxiety abnormal behaviour changes behaviour may affect people taking june us food drug administration fda concluded review possibility neuropsychiatric side effects leukotriene modulator although clinical trials revealed increased risk insomnia postmarketing surveillance showed drugs associated possible increase suicidal behavior side effects agitation aggression anxiousness dream abnormalities hallucinations depression irritability restlessness september pediatric advisory committee drug safety risk management advisory committee met discuss pediatricfocused safety review neuropsychiatric events march fda required boxed warning montelukast strengthen existing warning risk neuropsychiatric events associated drug wake increase case reporting neuropsychiatric events around time initial communications concern fda boxed warning advises health care providers avoid prescribing montelukast patients mild symptoms particularly allergic rhinitis many allergy medicines safely effectively manage fdas selfconducted data analysis comparison received case reports dependent peoples selfclaims propensity developing neuropsychiatric disorders montelukast use outpace inhaled corticosteroids statistically significant risks newonset neuropsychiatric disorders among males females patients years older patients psychiatric history fda communication prescribing information changes first publicized addition fdas selfconducted data analysis also summarized findings saying exposure montelukast significantly associated decreased risk treated outpatient depressive disorder decreased risks seen among patients history psychiatric disorder patients years well years older females treated outpatient depressive disorder refers patients sought treatment specifically depressive disorders outpatient psychiatric montelukast inhibitor drug metabolizing enzyme part cytochrome system therefore theoretically possible combination montelukast substrate eg amodiaquine antimalarial drug could increase plasma concentrations however clinical studies shown minimal interactions montelukast substrate drugs likely due high plasma protein binding exhibited montelukast leukotriene receptor antagonist family works blocking action leukotriene lungs resulting decreased inflammation relaxation smooth montelukast functions leukotriene receptor antagonist cysteinyl leukotriene receptors consequently opposes function inflammatory mediators leukotrienes produced immune system serve promote bronchoconstriction inflammation microvascular permeability mucus secretion asthma leukotriene receptor antagonists sometimes colloquially referred leukasts two genes interest catalyze two major steps biosynthetic pathway leukotrienescitation needed montelukast may affect nerve remyelination combination may cause clinical benefits side effects singulair covered us patent expired august day fda approved several generic versions united states patent trademark office launched reexamination patent covering singulair may decision driven discovery references included original patent application process references submitted article one partners online research community focused finding literature relating existing patents references included scientific article produced merck employee active ingredient singulair previously filed patent submitted technology seven months later us patent trademark office determined patent question valid based initial reexamination new information provided submitting decision december scheringplough merck sought permission market combined tablet loratadine montelukast however fda found benefit combined pill seasonal allergies taking two drugs april issued notapprovable letter mont montelukast stands montreal place merck msd developed montelukast sold variety brand names including monalast ziska pharmaceuticals ltd montenaaf naafco pharma apex montene square monteflo tukast l india reversair aci bangladesh monas miralust montiva provair montril lumona lumenta arokast trilock bangladesh ventair nepal montika pakistan montelair brazil zykast philippines though combined levocetirizine desmont levmont aircomb notta turkey topraz south africa airon venezuelacitation needed httpsenwikipediaorgwikimontelukast